Gilead earnings beat Street estimates, writedown taken on cancer drug
By Deena Beasley (Reuters) – Gilead Sciences Inc on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral Veklury, but the company…